Gene delivery into the spinal cord provides a potential approach to the treatment of spinal cord traumatic injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. These disorders progress over long periods of time, necessitating a stable expression of functional genes at therapeutic levels for months or years. We investigated in this study the feasibility of achieving prolonged transgene expression in the rat spinal cord through repeated intrathecal administration of plasmid DNA complexed with 25 kDa polyethylenimine (PEI) into the lumbar subarachnoid space. With a single injection, DNA/PEI complexes could provide transgene expression in the spinal cord 40-fold higher than naked plasmid DNA. The transgene expression at the initial level persisted for about 5 days, with a low-level expression being detectable for at least 8 weeks. When repeated dosing was tested, a 70% attenuation of gene expression was observed following reinjection at a 2-week interval. This attenuation was associated with apoptotic cell death and detected even using complexes containing a noncoding DNA that did not mediate any gene expression. When each component of the complexes, PEI polymer or naked DNA alone, were tested in the first dosing, no reduction was found. Using polyethylene glycol (PEG)-grafted PEI for DNA complexes, no attenuation of gene expression was detected after repeated intrathecal injections, even in those rats receiving three doses, administered 2 weeks apart. Lumbar puncture is a routine and relatively nontraumatic clinical procedure. Repeated administration of DNA complexed with PEG-grafted PEI through this less invasive route may prolong the time span of transgene expression when needed, providing a viable strategy for the gene therapy of spinal cord disorders.
Introduction
Spinal cord injury and other degenerative neurological illnesses like amyotrophic lateral sclerosis and spinal muscular atrophy come with devastating effects on the individual, and are associated with high societal costs because of chronic care and lost productivity. Gene therapy through gene transfer into the central nervous system (CNS) holds promise in treating these disorders. 1 Since most spinal cord disorders evolve over years, chronic therapy may necessitate a long-term transgene expression at therapeutic levels. Several viral gene vectors, including adenoviruses and herpes simplex viruses, have been efficient in attaining persistent gene expression in the spinal cord. 2, 3 However, potential side effects of induction of immunological and pathogenic complications may limit the widespread use of these viral vectors, particularly in repeated administration.
Nonviral gene delivery systems based upon plasmid DNA/chemical complexes are quickly gaining recognition as an alternative to viral gene vectors for their potential in avoiding problems inherent in viral systems. Among the nonviral vectors in use, the polycationic polymer polyethylenimine (PEI) has shown high transfection efficiency both in vitro and in vivo. 4 Once in the nervous system, PEI may mediate DNA transfection in terminally differentiated nondividing neurons. [4] [5] [6] After direct brain injection, PEI/DNA complexes can provide transgene expression levels higher than those obtained with the HIV-derived vector and within the same range as that achieved with adenoviral vectors. 5 Owing to the transient expression nature of plasmid DNA, nonviral gene therapy protocols would require repeated administrations in order to achieve efficient long-term expression of therapeutic genes. Several laboratories have addressed this issue in peripheral organs using repeated intravenous or intratracheal administration. [7] [8] [9] Unique attributes of the CNS, includ-ing limited access because of the skull and the bloodbrain barrier and high vulnerability to injury, pose severe obstacles to safe repetitive gene delivery. The commonly used gene delivery techniques, like direct injection into the brain and spinal cord tissues, are highly invasive and not practical in a repeat injection scheme. One way to achieve repeated CNS administration is to implant a cannula connected to a subcutaneous reservoir that provides continuous infusion of a therapeutic gene. 10, 11 For gene delivery into the spinal cord, a less invasive method, thus potentially allowing multiple administrations, is lumbar intrathecal injection into the cerebrospinal fluid (CSF). Lumbar puncture poses little danger to the spinal cord as the relative wide subarachnoid space at the site allows a certain degree of mobility of nerves within the CSF, thus avoiding damage caused by needle puncture. This method leads to relatively widespread gene expression in the CNS, and is suitable in treating degenerative neurological and neurogenetic disorders, spinal cord trauma, pain as well as fatal leptomeningeal metastases. 10, [12] [13] [14] We showed in this study the feasibility of achieving gene transfer in the spinal cord by intrathecal administration of PEI/DNA complexes in rats. We showed further that repeated administration of these complexes at biweekly intervals could achieve unattenuated transgene expressions if the PEI was modified with a polyethylene glycol (PEG), a group of synthetic polymers that are frequently used to improve solubility and reduce antigenicity, immunogenicity and toxicity of the molecules to which they are attached. 15 
Results
Transgene expression in the spinal cord after intrathecal delivery of PEI/DNA complexes We first evaluated transgene expression induced by intrathecal injection of naked plasmid DNA. Various amounts, from 2 to 40 mg, of luciferase-encoded plasmid DNA driven by the CMV IE enhancer chicken b-actin promoter (pCAGLuc) were injected at lumbar levels. Transgene expression in the spinal cord was dosedependent, reaching a maximum level at 20 mg DNA (Figure 1a ). When the plasmid DNA was complexed with PEI, transgene expression improved significantly. For example, the expression level induced by the PEI complexes containing 4 mg of DNA could be 40-fold of that induced by the same amount of the naked plasmid DNA. At their maximum levels, the gene expression mediated by PEI/DNA complexes (4 mg of DNA at N/P ratio 15) is about five-fold that mediated by 20 mg of naked DNA (Figure 1b) . The efficiency of PEI/DNA complexes in mediating transgene expression after intrathecal injection was related to charge ratios. A maximum efficiency was observed at a charge ratio of 15 equivalents of PEI nitrogen per DNA phosphate, with a luciferase activity of 2.5 Â 10 5 RLU/spinal cord at 4 mg of DNA (Figure 1c) . Luciferase activity decreased when the charge ratio was increased to 20 equivalents. Luciferase activity was detected along the entire spinal cord, with peak levels in the thoracic, lumbar and sacral regions that are close to the injection site (Figure 3a) . In a time course study of PEI/DNA complexes, the intrathecal injection yielded a significant level of luciferase in the spinal cord as early as 1 day after injection (Figure 1d ). This level of transgene expression retained for at least 5 days. After that it rapidly declined by an order of magnitude at day 7. However, this lower level of expression was still detectable even after 8 weeks ( Figure  1d ). To determine histologically the regions and cell types in the spinal cord that expressed luciferase, cryostat sections of the lumbar and thoracic parts of the spinal cord were stained using antibodies against luciferase. A strong staining was seen in spinal meninges in animals receiving PEI/DNA complexes (Figure 2a) . The luciferase activity in this region accounted for 50% of the total activity in the whole spinal cord (Figure 3b 
Repetitive injection: attenuation of gene expression upon readministration
To test whether long-term gene expression can be achieved with repeated injections of PEI/DNA complexes, rats were given a second injection at different PEG-PEI and gene expression in the spinal cord L Shi et al times after the first administration, and luciferase activities were assayed 48 h later. Control animals were injected with 5% glucose, a solution used for the preparation of PEI/DNA complexes, at the first time, followed by the same treatment done to their counterparts. As shown in Figure 4 , a repeat injection of PEI/ DNA 2 weeks after the initial one yielded a transgene expression that was 70% below control value. However, as the time interval between the two injections increased up to 4 weeks, the reduction of gene expression was not observed.
To identify the cause for the attenuation, we tested each component of the PEI/DNA complexes separately. Injection of naked DNA alone, up to a dose of 20 mg, or PEI polymer alone, at a dose similar to that used for DNA complexes preparation, caused no attenuation of gene expression upon re-injection of PEI/DNA complexes 2 weeks later ( Figure 5 ). On the contrary, injection of complexes containing a noncoding plasmid with a nonfunctional promoter did induce the reduction of gene expression ( Figure 5 ). The degree of attenuation worsened with an N/P ratio increasing from 15 to 50. These results indicate that PEI/DNA complexes were the cause for the inhibition observed, not the components alone or transgene expression upon the first dosing.
Knowing that PEI exhibits some cytotoxicity, 16 we next examined the histology of the spinal cord that received intrathecal injection of PEI/DNA complexes 2 weeks earlier. H&E staining revealed no histopathological and inflammatory alterations (Figure 6a and b). However, TUNEL staining of the sections from the same animal revealed abnormally bright nuclei in some cells, an indication of nuclei fragmentation and apoptotic cell death. TUNEL-positive cells were found mainly in the meninges of the lumbar and thoracic spinal cord ( Figure  6d ). Some TUNEL-positive cells were also found in the 
PEI PEGylation eliminates attenuation of gene expression in repetitive administration
Several studies have shown that PEI PEGylation may reduce its cytotoxicity. [17] [18] [19] We synthesized a conjugate consisting of PEI covalently modified with PEG. The ratio of PEG versus PEI was 2.5, as determined from 1 H-NMR spectra using integral values obtained for the -CH 2 CH 2 O-protons of PEG and -CH 2 CH 2 NH-protons of PEI. PEGylation of PEI at this ratio did not significantly affect the amount of polymer required to retard the migration of DNA ( Figure 7 ). We then studied the influence of PEGylation on the size of DNA complexes using light scattering (Table 1) . Complexes were prepared using DNA and polymer concentrations as used for our in vivo experiments. Two peaks were observed in the size measurement of PEI/DNA complexes at N/P ratio 15. The dominant one, which accounted for 44% of complexes, showed an average diameter of 136 nm and another (28%) was 754 nm. This second portion was probably because of aggregation of complexes. For PEGylated PEI, we observed a small complex diameter of 93 nm. This is consistent with a recent report 20 demonstrating that attaching one or two PEG to PEI could enhance DNA condensation forming compact complexes smaller than those complexed by PEI alone. Furthermore, the percentage of the second portion of PEG-PEI complexes with a much larger diameter (826 nm) decreased in comparison to PEI complexes, accounting for only 7%. PEGylated PEI was significantly less toxic in two neuronal precursor cells lines, PC12 and NT2/D1 cells ( Figure 8 ). As a matter of fact, PEG-PEI stimulated cell proliferation in both cell lines at lower concentrations ( Figure 8) . In another experiment, cell toxicity was tested in NT2/D1 cells using DNA/polymer complexes instead of polymer alone to mimic the in vivo use of these polymers. DNA/polymer complexes were more toxic than polymers that did not interact with DNA ( Figure 9 ). PEGylation reduced PEI cell toxicity also when the polymer formed complexes with DNA ( Figure 9 ). As well, apoptosis decreased significantly in NT2/D1 cells after PEI PEGlyation, as demonstrated by TUNEL staining. For example, 0.5 mM of PEI induced typical apoptotic nuclear morphology, with chromatin fragmentation into bright patches (Figure 6f) . The same concentration of PEG-PEI did not convert any cells into TUNEL positive (Figure 6e) .
We then tested DNA complexed with PEG-PEI in our intrathecal gene delivery model. Transgene expression in the spinal cord was dose-dependent, reaching a plateau at 4 mg DNA (Figure 10a ). The efficiency of PEG-PEI/ DNA complexes in mediating transgene expression increased when charge ratios were increased, with the highest luciferase activity of 4.8 Â 10 5 RLU/spinal cord at N/P ratio 40 (Figure 10b ). PEI PEGylation did not change tissue and cellular distribution patterns of transgene expression (data not shown). In a repetitive administration experiment, animals were given a second injection of polymer DNA complexes 2 weeks after the first administration of PEG-PEI/DNA complexes or 5% glucose vehicle solution and gene expression was analyzed 48 h later. We observed no difference in terms of gene expression levels between animals receiving PEG-PEI/ DNA complexes and control animals ( Figure 11 ). In another experiment, each animal received three doses, administered 2 weeks apart. There was no evidence of inhibitory effects of previous administrations on gene expression imposed on the next administration ( Figure  11 ).
Discussion
The blood-brain barrier precludes a vascular route of transgene delivery to the CNS. Direct stereotactic injection into specific location therefore becomes the most widely used approach for gene delivery to the CNS. This procedure is highly invasive and the resulting transgene expression can usually be detected only in the immediate vicinity of the injection site. On the other hand, intraventricular or intrathecal injection into CSF may reduce direct damage to CNS tissues and provide means for widespread expression of transgenes in the whole organ. Lumbar puncture is a routine and relatively nontraumatic clinical procedure, allowing a safe repeated administration for gene delivery. The distribution of gene expression in the CNS after lumbar injection is, however, relatively limited, probably because of CSF flow. In this study, the transgene expression was still localized in the sacral, lumbar and thoracic regions, although lower but detectable gene expression could be observed in the cervical regions and the brain. This distribution was not improved by using PEG-grafted PEI. Cellular distribution of transgene expression mediated by PEI observed in this study was consistent with the report by Abdallah et al 5 and somehow different from the studies using cationic liposome 13 or adenoviral vectors, 21 which showed a restricted gene expression in meninges.
Transient transgene expression can be one disadvantage associated with nonviral gene delivery systems, dependent on the applications. One way to overcome this problem is repetitive administrations. In the case of cationic lipidic vectors, repetitive intravenous administrations are not effective at frequent intervals. 7, 8, 22 Apoptosis and inactivation of gene expression triggered by interferon-g and tumor necrosis factor-a, which may be induced by direct immunostimulatory effects of unmethylated CpG sequences in plasmid DNA, have been identified as two causes, among others, for this ineffectiveness. 7, 22 The same mechanism may be in force when PEI is used as a delivery system for plasmid DNA and be responsible for observed apoptotic cell death in the spinal cord after intrathecal injection of PEI/DNA complexes. The CNS is considered to be an immune privileged site and inflammatory and immune cells do not function in the CNS as efficiently as in other organs. However, CNS ventricles and parenchyma are immunologically separate. Administration of antigens and viruses into the CSF elicited immune responses, probably by antigenic presentation in the deep cervical lymph nodes. 23, 24 Overexpression of gene products may cause cell death and apoptosis, 25 but seems unlikely to act as a main cause for what was observed in this study, in view of the observation that noncoding plasmid DNA complexed with PEI inhibited subsequent gene expression too. Direct toxic effects of PEI/DNA complexes, especially their aggregates or precipitates, may also be responsible for cell death. It is of note that apoptosis was observed almost exclusively in meninges. The pia mater of spinal meninges forms the boundary of the CSF and spinal parenchyma, acting as a barrier in transporting DNA/polymer complexes from the CSF to the spinal cord tissues. Consistent with a previous study using intracerebro-ventricular injection of PEI/DNA complexes, 5 we have observed significant transgene expression in CNS parenchyma after CSF gene delivery, indicating the PEI/DNA complexes may penetrate through the pia mater. No obvious cell death in the gray and white matters of the spinal cord indicates further that PEI/DNA complexes entering the spinal parenchyma may not be toxic to glial cells and neurons at these low doses. This is consistent with our previous report that PEI/DNA complexes delivered through a retrograde axonal transport caused no toxicity in brainstem neurons at concentrations for efficient DNA transfection. 26 However, PEI/DNA complexes do not disperse well, especially at higher N/P ratios. Aggregates of the complexes could precipitate on the surface of the pia/dura mater, Figure 11 Repetitive injection with DNA/PEG-PEI complexes. In the experiment with two injections, rats were first given 5% glucose (vehicle control group) or 4 mg of DNA complexed with PEG-PEI at N/P ratio 20 (PEG-PEI group) and then a second injection of 4 mg of DNA complexes for all animals 2 weeks later. In the experiment with three injections, rats were given two doses of 5% glucose (vehicle control group) or 4 mg of DNA complexed with PEG-PEI (PEG-PEI group) followed by a third injection of 4 mg of DNA complexes for all animals at biweekly intervals between the three administrations. Rats were killed 48 h after the last injection for luciferase activity assay. Eight rats per group were used.
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causing the death of leptomeningeal cells. Further investigation is required to clarify the mechanism of apoptosis observed in the current study.
The apoptotic cell death observed in this study was associated with attenuation of transgene expression following a second injection. As shown in this study, the attenuation is not because of the PEI polymer itself because injection of the polymer alone had no effects. Neither is the attenuation caused by the gene products because injection of the complexes containing noncoding plasmid DNA was as inhibitory as those containing functional plasmid DNA. It appears that PEI/DNA complexes, but not the separate component alone, are the cause of the attenuation. PEI polymer alone is probably capable of inducing apoptosis at higher concentrations, as shown in the in vitro experiment of this study. In an in vivo study injecting PEI alone into the CSF, such as the one reported here, opsonization of the highly positively charged polymer might reduce its cytotoxic effects. Indeed, PEI polymer alone was less toxic than PEI/DNA complexes in in vitro cell viability assays using serum-containing medium ( Figure 9 ). Relatively inefficient cellular uptake of the branched 25 kDa PEI compared to the PEI/DNA nanocomplexes may also have accounted for this diminished toxicity. Naked plasmid DNA alone is not stable in the body fluid and may degrade rapidly. DNA degradation may decrease CpG contents, 7,27 thus eliminating CpG-induced immune responses.
PEI PEGylation in this study eliminates apoptosis and attenuation of gene expression upon a second administration of DNA/polymer complexes. The exact underlying mechanism is unclear. One drawback of using polycations, including PEI, is poor solubility of their complexes with DNA, 18 especially at a higher N/P ratio. Precipitates or aggregates of these DNA/polymer complexes could be more toxic than their nonaggregated counterparts and polymers alone, as indicated in our finding that the higher the N/P ratio of the complexes, the stronger the attenuating effect on subsequent gene expression. PEGylation often can improve the solubility of macromolecules, minimize aggregation of particulates and reduce their interaction with proteins in the physiological fluid. Previous studies have shown that PEGylation of PEI reduced the surface charge of PEI/ DNA particles, increased their dispersion ability at high concentrations, decreased plasma protein binding and erythrocyte aggregation, prolonged blood circulation and reduced systemic toxicity after tail vein injection. [17] [18] [19] Some of these effects may have contributed to the improvement in gene expression upon repeated dosing observed in the present study. It has indeed been reported that PEGylation of polycations provides improved transfection efficiency. 20, [28] [29] [30] [31] Proteins and peptides modified by PEG usually become less immunogenic and antigenic, because of reduced immune recognition caused by PEG-induced steric hindrance. [32] [33] [34] Covalent attachment of PEG to the surface of the adenovirus 35, 36 reduces both the humoral and cellular immune responses against viral proteins, allowing substantial gene expression of the vector upon re-administration without compromising the immune system of immunocompetent animals. 37 There exists the possibility that PEGylation of PEI in the present study might alter immune stimulatory effects of CpG motifs in plasmid DNA once PEI/DNA complexes were formed, thus affecting cell susceptibility and gene expression profiles in repetitive administration experiments.
In summary, we have confirmed the feasibility of using PEGylated PEI for repetitive administration of DNA/ polymer complexes into the spinal cord through lumbar intrathecal injection. A prolonged transgene expression at a significant level was demonstrated for up to 6 weeks after three repeated dosing. Advantages of this method in spinal cord gene therapy include minimal damage to neural tissues, flexibility in controlling the therapeutic period, and possibility of achieving widespread gene expression. 
Materials and methods

Synthesis of PEG-PEI
A volume of 1 ml of PEI (0.1 M) was mixed with 60 ml of NHS-PEG-MAL solution (5 mM). The mixture was stirred at room temperature for 45 min, after which 50 ml of 1 M of glycine was added to quench the reaction. The compound was purified by PD-10 column eluting with PBS solution (PBS containing 5 mM EDTA), centrifugal filter and dialysis against water. The ratio of PEG and the PEI in the copolymer was determined from 1 H-NMR spectra using integral values obtained for the -CH 2 CH 2 O-protons of PEG and the -CH 2 CH 2 NHprotons of PEI.
Plasmid
The plasmid used was pCAGLuc (kindly donated by Yoshiharu Matsuura, National Institute of Infectious Diseases, Tokyo, Japan), encoding firefly luciferase driven by a composite promoter CAG consisting of the CMV IE enhancer, chicken b-actin promoter and rabbit bglobin polyadenylation signal. All plasmid DNAs were amplified in E. coli and purified according to the supplier's protocol (Qiagen, Hilden, Germany). The quantity and quality of the purified plasmid DNA was assessed by optical density at 260 and 280 nm and by electrophoresis in 1% agarose gel. The purified plasmid DNA was resuspended in TE buffer and kept in aliquots at a concentration of 1 mg/ml. To construct the noncoding plasmid pLuc-s, the SalI/HindIII luciferase fragment of pGL-3 basic vector (Promega, Madison, WI, USA) was excised and replaced by SalI/HindIII CAGLuc cassette from pCAGLuc. pLuc-s did not show any luciferase expression after in vitro cell transfection and in vivo intrathecal injection.
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Preparation and characterization of DNA/polymer complexes
The PEI or PEG-PEI/DNA complexes were prepared according to Boussif et al. 4 Plasmid DNA was diluted in 5% glucose to the chosen concentration (usually 0.5-2 mg/ml). After vortexing, the appropriate amount of 0.1 M PEI or PEG-PEI was added dropwise into DNA solutions and the solutions revortexed. The required amount of PEI, according to DNA concentration and number of equivalents needed, was calculated by taking into account that 1 mg DNA contains 3 nmol of phosphate and that 1 ml of 0.1 M PEI holds 100 nmol of amine nitrogen. For agarose gel electrophoresis, polymer DNA complexes mixed with a loading buffer were loaded onto an ethidium bromide containing 1% agarose gel. Gel electrophoresis was run at room temperature in TEB buffer at 80 V for 60 min. DNA bands were visualized by a UV (254 nm) illuminator. For complex size measurements, an N4 Plus Submicron Particle Sizer (COULTER, USA) was used. Scattering light was detected at 901, running of 200 s at room temperature. For data analysis, the refractive index medium (1.332) of 5% glucose was used. The data obtained were analyzed in the Unimodal Analysis mode.
Animals and injection procedures
Adult male Wistar rats (8 weeks old, 180-200 g) were used throughout the study. Before each injection, the animals were anesthetized by an i.p. injection of sodium pentobarbital (60 mg/kg). The lumbar injection was given using a 10 ml micro-syringe connected with a 26-gauge needle, after the skin around L4-L5 was exposed. The slight movement of the tail indicated the proper injection into the subarachnoid space. For each rat, 20 ml of 5% glucose solution containing 4 mg of plasmid DNA complexed with PEI or PEG-PEI were given by two injections. After a slow injection of 10 ml of polymer DNA complexes over 2-5 min, the syringe was left in place for 5 min to limit diffusion of the DNA from the injection site owing to the backflow pressure. The skin was closed with surgical clips after the injection. The animals were kept warm until they recovered.
Luciferase activity assay
Animals were intraperitoneally anesthetized with sodium pentobarbital and then perfused transcardially with 0.1 M phosphate-buffered saline (PBS, 200 ml/rat). After the perfusion, the whole spinal cord was exposed. The spinal cord was separated into cervical, thoracic and lumbar/sacral parts before homogenization. For some experiments, meninges were separated from the corresponding parts of the spinal cord. The tissue samples were homogenized with 400 ml of lysis buffer (Promega), and then subjected to three freeze-thaw cycles. The lysate was centrifuged at 14 000 g for 5 min at 41C, and 100 ml of supernatant was used for the luciferase activity assay at room temperature employing an assay kit from Promega. Measurements were made in a single-well luminometer (Berthold Lumat LB 9507, Germany) for 10 s.
Cell viability assay
NT2 cells were cultured in DMEM supplemented with 10% FCS at 371C, 5% CO 2 , and 95% relative humidity. PC12 cells were cultured in rat tail collagen-coated dishes in RPMI 1640 medium supplemented with 5% FCS and 10% heat-inactivated horse serum. For cell viability assay, the cells (10 000 cells/well) were seeded into 96-well microtiter plates (Nunc, Wiesbaden, Germany). After 24 h, culture media were replaced with serum-supplemented tissue culture media containing serial dilutions of polymer or polymer/DNA complexes solutions and the cells were incubated for 24 h. In some experiments, the cells were treated for 3 h before changing back to normal culture media and the cell viability assay was done 21 h later. For cell viability assay, 20 ml sterile filtered MTT (5 mg/m) stock solution in PBS was added to each well, reaching a final concentration of 0.5 mg MTT/ml. After 4 h, unreacted dye was removed by aspiration. The formazan crystals were dissolved in 100 ml/well DMSO (BDH Laboratory Supplies, England) and measured spectrophotometrically in an ELISA plate reader (Model 550, Bio-Rad) at a wavelength of 595 nm. The spectrophotometer was calibrated to 0 absorbance using culture medium without cells. Quintuplicate determinations for each treatment were performed. The relative cell growth (%) related to control cells cultured in media without polymer or polymer/DNA complexes was calculated by [A] test/[A] control Â 100.
Histological examination and immunostaining
At 2 or 14 days after PEI/DNA intrathecal injection, animals were anesthetized with sodium pentobarbital and perfused transcardially with saline solution (200 ml) followed by 150 ml of ice-cold fixative (4% paraformaldehyde, 0.05% glutaraldehyde in PBS). Tissues in lumbar and thoracic portions were removed, respectively, from the whole spinal cord and kept at À801C until sectioning. For H&E staining, paraffin-embedded sections were prepared. For immunostaining, the tissues were cut in short length and fixed on the plate with tissue freezing medium. After setting up on an ultramicrotome at À201C (OT) and À151C (CT), respectively, sections of thickness 35 mm were cut. The sections were transferred to a gelatin-coated slide and fixed with acetone. A goat antiluciferase (1/200, in PBS 1% BSA, Dako) and an FITC-conjugated anti-goat polyclonal antibody were used as the primary and secondary antibodies, respectively. After antibody incubation and washing, the sections were mounted in FluorSave (Calbiochem). Photographs were taken with digital camera attached to the microscope.
TUNEL staining
For in vitro TUNEL staining, NT2 cells were seeded in a 24-well plate with glass slides in each well, grown and treated as above. The slides were then fixed with a freshly prepared paraformaldehyde solution (4% in PBS, pH 7.4). After 1 h of fixation at RT, the slides were rinsed with PBS and incubated with blocking solution (3% H 2 O 2 ) for 10 min at RT. The slides were then incubated in a permeabilization solution containing 0.1% Triton s X-100 in 0.1% sodium citrate for 2 min at 41C. After rinsing the slides twice with PBS, 50 ml of TUNEL reaction solution from the TUNEL staining kit (Roche) was added to each sample. After 60 min incubation at 371C and washing, samples were analyzed under a fluorescence microscope. For the negative control, samples were PEG-PEI and gene expression in the spinal cord L Shi et al incubated in 50 ml of a label solution without terminal transferase. The same procedure was used for the tissue sectioning samples from in vivo studies.
